Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
phenoxodiol · 3 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Daily Phenoxodiol + weekly carboplatin |
| 2 | ACTIVE_COMPARATOR | Daily phenoxodiol placebo + weekly carboplatin |
| A | EXPERIMENTAL | Patients with chemotherapy naïve androgen independent disease |
| B | EXPERIMENTAL | Patients with rising PSA after radical prostatectomy or radiotherapy that are androgen dependent |
| Arm A | EXPERIMENTAL | Phenoxodiol IV 3 mg/kg combined with cisplatin 40 mg/m2 on Day 2 6 week cycles |
| Arm B | EXPERIMENTAL | Phenoxodiol IV 3 mg/kg combined with paclitaxel 80 mg/m2 on Day 2 6 week cycles |
| Name | Type | Description |
|---|---|---|
| phenoxodiol | DRUG | 400mg phenoxodiol three times daily in 28 day cycles. |
| carboplatin | DRUG | AUC=2 weekly in 28 day cycles |
| placebo | DRUG | every 8 hours daily in 28 day cycles |
| cisplatin | DRUG | IV 40 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met. |
| paclitaxel | DRUG | IV 80 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met. |
Inclusion Criteria: * Histologically-confirmed ovarian, fallopian, or primary peritoneal carcinoma of epithelial origin * Recurrent or persistent advanced disease * Have measurable disease * Undergone at least two courses of therapy with a platinum drug (cisplatin or carboplatin) and have responded...
Phenoxodiol is an investigational small molecule being studied for the treatment of prostate cancer and fallopian tube cancer. It is developed by Lite Strategy, Inc. (ticker: LITS). The drug is currently in Phase 2 clinical development for these oncology indications.
Phenoxodiol is a small molecule therapeutic agent. Its mechanism of action involves targeting cancer cells, though the specific molecular target has not been disclosed. It is being evaluated for its potential to treat prostate cancer and fallopian tube cancer.
Phenoxodiol is developed by Lite Strategy, Inc., a biopharmaceutical company traded under the ticker symbol LITS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in oncology indications.
Phenoxodiol is currently in Phase 2 clinical development. It has completed two clinical trials, including a Phase 1 and a Phase 3 study, with a total enrollment of 207 participants. The drug is investigational and not yet approved by regulatory authorities.
Phenoxodiol has completed two clinical trials. NCT00091377 was a Phase 1 study combining phenoxodiol with cisplatin or paclitaxel in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer. NCT00382811 was a Phase 3 study of weekly carboplatin with or without phenoxodiol in platinum-resistant ovarian cancer. Both trials are completed.
Phenoxodiol is also known by its chemical name, 2H-1-benzopyran-7-ol, 3-(4-hydroxyphenyl)-. It is being studied under this name in clinical trials for prostate cancer and fallopian tube cancer. No other alternative names have been reported.